title: Bortezomib: a new therapeutic option for POEMS syndrome.
abstract: OBJECTIVE
  POEMS syndrome with its classical five findings (Polyneuropathy, Organomegaly, Endocrinopathy, M protein, and Skin changes) is a rare multisystem disease. Proinflammatory and proangiogenic cytokines play important roles in its pathogenesis. Treatment options are still debated.
  
  
  METHODS
  We present a 65-year-old man with POEMS syndrome who was successfully treated with bortezomib.
  
  
  RESULTS
  After seven cycles of this protocol, serum M protein level declined to normal range, and near-to-complete remission was achieved. His symptoms of polyneuropathy improved dramatically.
  
  
  CONCLUSIONS
  Bortezomib may be an effective and safe therapeutic option for patients with POEMS syndrome.
authors.affiliation: Department of Hematology, Marmara University School of Medicine, Marmara University, Istanbul, Turkey. isikkaygusuz@yahoo.com
authors.forename: Isik
authors.initials: I
authors.lastname: Kaygusuz
authors.forename: Hakan
authors.initials: H
authors.lastname: Tezcan
authors.forename: Mustafa
authors.initials: M
authors.lastname: Cetiner
authors.forename: Ozan
authors.initials: O
authors.lastname: Kocakaya
authors.forename: Ant
authors.initials: A
authors.lastname: Uzay
authors.forename: Mahmut
authors.initials: M
authors.lastname: Bayik
mesh_terms: D000970:Antineoplastic Agents / Q000008:administration & dosage*; D001897:Boronic Acids / Q000008:administration & dosage*; D000069286:Bortezomib; D006023:Glycoproteins / Q000097:blood; D006801:Humans; D008297:Male; D016878:POEMS Syndrome / Q000097:blood / Q000188:drug therapy*; D011719:Pyrazines / Q000008:administration & dosage*; D012074:Remission Induction
chemical_list: D000970:Antineoplastic Agents; D001897:Boronic Acids; D006023:Glycoproteins; D011719:Pyrazines; C023587:protein M (glycoprotein); D000069286:Bortezomib